Advanced searches left 3/3

Metastatic Triple-Negative Breast - Europe PMC

Summarized by Plex Scholar
Last Updated: 06 May 2022

* If you want to update the article please login/register

A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.

Although the heat shock protein HSP90 is a promising target, previous inhibitors have had challenges during manufacturing, including inadequate induction of the heat shock response and off-target effects leading to toxicity. SL-145 potently inhibited tumor formation, angiogenesis, and metastases concomitant with misregulation of the JAK2/STAT3 signaling pathway, contributing to tumor growth, angiogenesis, and metastases concomitant with dysregulation of the JAK2/STAT3 signaling pathway. Our findings support the possibility of SL-145 in suppressing metastatic TNBC independent of the HSR.

Source link: https://europepmc.org/article/MED/35501463


Palmatine Attenuates Metastatic Lung Colonization of Triple Negative Breast Cancer Cells.

Breast cancer has spread to the lungs by lymphatic or circulatory methods, with circulating tumor cells playing a key role. In this research, the lungs were investigated for triple negative breast cancer cells' metastatic colonization with palmatine. Methods: By the lymphatic system, 4T1 triple breast cancer cells were transplanted synergically to the female balb/c mice's thoracic duct. Conclusion: Palmatine preserved lung morphology and demonstrated therapeutic promise in aiding in the diagnosis of lung metastasis.

Source link: https://europepmc.org/article/MED/35496301


Immune checkpoint inhibitors plus chemotherapy in metastatic triple -negative breast cancer: A systematic review and meta-analysis

Purpose: Some studies have reported that immune checkpoint inhibitors have a promising effect in early triple-negative breast cancer patients, but the results are not clear in the rescue therapy setting. In metastatic TNBC patients, chemotherapy plus ICIs were used to measure the efficacy and safety of chemotherapy plus ICIs. Methods: We developed randomized controlled trials investigating the efficacy and safety of ICIs plus chemotherapy in metastatic TNBC after slyetically reviewing PubMed and EMBASE up to December 30, 2021. With mTNBC, both the ITT and PD-L1positive groups with mTNBC greatly improved PFS. However, ICIs plus chemotherapy failed to raise OS in PD-L1 positive or ITT populationgs. ICIs in patients with elevated PD-L1 levels can enhance not only PFS but also OS. Conclusion: With mTNBC, the meta-analysis found that adding ICIs to therapy significantly raised PFS in both ITT and PD-L1 positive populations.

Source link: https://europepmc.org/article/PPR/PPR479292


Emerging treatment strategies for metastatic triple-negative breast cancer.

Triple-negative breast cancer is a heterogeneous subtype of breast cancer with a pronounced phenotype and a poor prognosis, which is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of therapy for the majority of patients with metastatic TNBC, but the duration of response is often short and median overall survival is only 12-18 months.

Source link: https://europepmc.org/article/MED/35422881


Fatty acid β-oxidation targeted metastatic growth inhibition in triple negative breast cancer exploiting biotin-functionalized copolymer

Background: and purpose Carnitine palmitoyltransferase I, an integral outer mitochondrial protein and prime decider of fatty acid oxidation, has been regarded as a key therapeutic target for triple negative breast cancer progression and survival. The experimental approach CP4 was synthesized using either reversible addition fragmentation chain transfer or RAFT polymerization. The active binding of CP4 with CPT1 has been predicted by In silico computation modelling. The FAO-related protein expression profiles were determined by real-time quantitative reverse transcription PCR. In a female breast cancer mice model, antitumor functions were found. The main aims of CP4 to CPT1 were confirmed by Negative docking score and Ramachandran plot reviews. In turn, it triggered metastatic growth inhibition and apoptotic cell death in TNBC cells in turn. Conclusion and Implications of the CP4's may have the advantage of being a young FAO-targeted anticancer therapeutics, which may lead to a new breast cancer treatment plan that will be launched shortly.

Source link: https://europepmc.org/article/PPR/PPR478406

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions